Immunology - hbm holdings

Therapeutics

Developing Next Generation Therapeutics for Healthy Life

HOME / Therapeutics / Immunology

Pipeline

Oncology/Immuno-Oncology

Product(Partners) Target Indication Region Discovery Preclinical IND PH1 PH2 PH3 BLA Filing: view more

Porustobart HBM4003

CTLA-4

Melanoma, HCC^*, RCC^*& Other Advanced Solid Tumors

Melanoma, HCC^*, NEC/NET^* & Other Advanced Solid Tumors

NSCLC^* & Other Advanced Solid Tumors

Global

Global

Global; view more

HBM7008

B7H4x4-1BB

Solid Tumors

Ex-U.S. ¹; HBM7022

CLDN18.2xCD3

Solid Tumors

Global License to AstraZeneca; HBM1022

CCR8

Solid Tumors

Global; view more

HBM1020

B7H7

Solid Tumors

Global; HBM1007

CD73

Solid Tumors

Global; HBM9033

MSLN ADC

Solid Tumors

Global; HBM9027

PD-L1xCD40

Solid Tumors

Global; HBM1047

CD200R1

Solid Tumors

Global; HBM7004

B7H4×CD3

Solid Tumors

Global; HBM9014

LIFR

Solid Tumors

Global

Immunology

Product(Partners) Target Indication Region Discovery Preclinical IND PH1 PH2 PH3 BLA Filing: view more

Batoclimab HBM9161(HanAll)

FcRn

MG^*

TED^*

Greater China License to CSPC

Greater China License to CSPC; HBM9378

TSLP

Asthma

Global; HBM9022(AbbVie; Utrecht University; Erasmus MC)

SARS-COV-2

COVID-19

Global License to AbbVie

HBM
Partner
Registrational Clinical Trial
Monotherapy
PD1 / Chemo
Breakthrough Therapy Designation

* HCC = Hepatocellular Carcinoma

* RCC = Renal Cell Carcinoma

* NEC = Neuroendocrine Carcinoma

* NET = Neuroendocrine Tumour

* NSCLC = Non-Small Cell Lung Cancer

* MG = Myasthenia Gravis

* TED = Thyroid Eye Disease

* The U.S. rights of HBM7008 is out-licensed to Cullinan Oncology in February 2023

Publications

A Phase I Study of HBM4003, an anti-CTLA-4 Heavy Chain Only Monoclonal Antibody, in Combination with Toripalimab in Advanced Melanoma

Presented at ESMO Immuno-Oncology Congress 2022
Innovative B7H4 x CD3 & B7H4 x 4-1BB Bispecificsfor Solid Tumor Therapies

Presented at 13th Annual Summit World Multispecifics, 2022
An anti-CTLA-4 heavy chain-only antibody with enhanced T reg depletion shows excellent preclinical efficacy and safety profile

Gan X, Shan Q, Li H, Janssens R, Shen Y, He Y, Chen F, van Haperen R, Drabek D, Li J, Zhang Y, Zhao J, Qin B, Jheng MJ, Chen V, Wang J, Rong Y, Grosveld F. An anti-CTLA-4 heavy chain-only antibody with enhanced T_reg depletion shows excellent preclinical efficacy and safety profile. Proc Natl Acad Sci U S A. 2022 Aug 9;119(32):e2200879119. doi: 10.1073/pnas.2200879119. Epub 2022 Aug 4. PMID: 35925889.
TNF-α inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China

Dong, Y., Wang, S., Cong, L. et al. TNF-α inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China. Int Ophthalmol (2022). https://doi.org/10.1007/s10792-022-02245-1
Therapeutic Response and Possible Biomarkers in Acute Attacks of Neuromyelitis Optica Spectrum Disorders: A Prospective Observational Study

Wang J, Cui C, Lu Y, et al. Therapeutic Response and Possible Biomarkers in Acute Attacks of Neuromyelitis Optica Spectrum Disorders: A Prospective Observational Study. Front Immunol. 2021 Aug 4;12:720907. doi: 10.3389/fimmu.2021.720907. PMID: 34421925; PMCID: PMC8372759.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers

Yap DYH, Hai J, Lee PCH, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers. Clin Transl Sci. 2021 Sep;14(5):1769-1779. doi: 10.1111/cts.13019. Epub 2021 Jul 16. PMID: 33742786; PMCID: PMC8504844.
SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model

Haagmans BL, Noack D, Okba NMA, et al. SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model. J Infect Dis. 2021 Jun 15;223(12):2020-2028. doi: 10.1093/infdis/jiab289. PMID: 34043806; PMCID: PMC8243397.
A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies

Wang C, van Haperen R, Gutiérrez-Álvarez J, et al. A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies. Nat Commun. 2021 Mar 17;12(1):1715. doi: 10.1038/s41467-021-21968-w. PMID: 33731724; PMCID: PMC7969777.
Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes

Fu D, Zhang G, Wang Y, et al. Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes. PLoS Biol. 2021 May 7;19(5):e3001209. doi: 10.1371/journal.pbio.3001209. PMID: 33961621; PMCID: PMC8133496.
A human monoclonal antibody blocking SARS-CoV-2 infection

Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020 May 4;11(1):2251. doi: 10.1038/s41467-020-16256-y. Erratum in: Nat Commun. 2020 May 14;11(1):2511. PMID: 32366817; PMCID: PMC7198537.
Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein

Widjaja I, Wang C, van Haperen R, et al. Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein. Emerg Microbes Infect. 2019;8(1):516-530. doi: 10.1080/22221751.2019.1597644. PMID: 30938227; PMCID: PMC6455120.
Cell Engager Summit Exclusive Speaker Interview

Presented at Cell Engager Summit, 2021
Preclinical evaluation of HBM7022, an HBICE™ 2+1 CLDN18.2 x CD3 bispecific antibody, for gastric cancer

Presented at Antibody Engineering & Therapeutics Europe (AET Europe), 2021
Development of fully human T-cell engaging bispecific antibodies targeting B7H4

Presented at Antibody Engineering & Therapeutics Europe (AET Europe), 2021
Discovery of potent and functional human antibodies against a new B7-family member, B7H7, for cancer immunotherapy

Presented at American Association for Cancer Research Annual Meeting (AACR), 2021
HCAb Based Bispecific Immune Cell Engager (HBICE) Platform Enables Fast And Convenient Generation of the Next Generation Bispecific Antibodies with High Potency, Promising Safety Profiles and Excellent Developability

Presented at Protein Engineering & Cell Therapy Summit Boston (PEGS Boston), 2020
HBM1022, a Novel Anti-CCR8 Antibody, Depletes Tumor-infiltrating Regulatory T cells via Enhanced ADCC Activity, Mediates Potent Anti-Tumor Activity

Presented at Society for Immunotherapy of Cancer’s (SITC) Annual Meeting, 2020
Novel Monoclonal Antibodies (mAbs) Targeting Human CCR8 Provide Potential Candidates for Next Generation Cancer Immunotherapy

Presented at Protein Engineering & Cell Therapy Summit Boston (PEGS Boston), 2020
HBM1007 – A Highly Potent Anti-CD73 mAb Candidate For Mono And Combination IO Therapy

Presented at American Association for Cancer Research Annual Meeting (AACR), 2020
BCMA x CD3 Bispecific Antibody – A novel HBICE™-based Molecule with Efficient Tumor Killing and Minimal Cytokine Release

Presented at Cell Engager Summit, 2020
A New Generation of Fully Human anti-CTLA-4 Heavy Chain Only Antibody

Presented at American Association for Cancer Research Annual Meeting (AACR), 2019

Follow
Harbour BioMed
on WeChat

Copyright © 2022 Harbour BioMed. All Rights Reserved 沪ICP备19015946号-1

FAMILY SITE